课题基金 / 基金详情

项目摘要

项目成果

JONATHAN P SCHNECK的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Description (provided by applicant): Central to understanding immune mechanisms that control viral responses is a more comprehensive understanding of the depth and breadth of antigen-specific immune responses. This will be particularly important in understanding why in the elderly population there is increased susceptibility to infection and less efficacy in vaccine strategies that are protective in younger cohorts. To study this we propose to apply a novel high-throughput, chip-based cellular microarray to characterize human immune responses during infections/vaccinations. Cellular microarrays are an emerging technology with promising applications in medical diagnostics, vaccine development, treatment of autoimmune diseases, and detection of potential agents of bioterrorism. In this R21 application we will focus specifically on influenza as influenza infections continue to have a major societal impact in terms of high morbidity and mortality, especially in the elderly. Specifically in Aim 1 we propose to demonstrate the efficacy of peptide-loaded HLA-Ig chips to examine both immunodominant and subdominant influenza specific immune responses in CTL expanded in vitro. Once generated and tested on the in vitro expanded cells we will analyze responses from vaccinated volunteers and patients who have documented influenza infection. This will be done for both elderly and younger cohorts to determine differences seen in responding CTL populations. While in this preliminary application the focus will be on the HLA A2 response to influenza, we plan to expand the work proposed here to cover other HLA class I and II alleles as well as other infectious diseases more broadly in the second U01 phase of the application.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A high-throughput nanoparticle assay to characterize cancer neoepitope-specific T cells
  • 批准号:
    10167008
  • 项目类别:
  • 资助金额:
    $16.38万
  • 财政年份:
    2020
  • 负责人:
    JONATHAN P SCHNECK
  • 依托单位:
The Johns Hopkins Translational ImmunoEngineering (JH-TIE) BTRC
  • 批准号:
    10436868
  • 项目类别:
  • 资助金额:
    $116.72万
  • 财政年份:
    2019
  • 负责人:
    JONATHAN P SCHNECK
  • 依托单位:
TR&D1: Engineering artificial Antigen Presenting Cells, aAPC, for Adoptive Immunotherapy
  • 批准号:
    10645127
  • 项目类别:
  • 资助金额:
    $31.68万
  • 财政年份:
    2019
  • 负责人:
    JONATHAN P SCHNECK
  • 依托单位:
JH-TIE Admin Core
  • 批准号:
    10436869
  • 项目类别:
  • 资助金额:
    $10.63万
  • 财政年份:
    2019
  • 负责人:
    JONATHAN P SCHNECK
  • 依托单位:
海外基金